GLP-1 Agonists Reimagined: The Tripartite Applications of the Semaglutide Hormone
Article Sidebar
Main Article Content
Abstract
Semaglutide, a GLP-1 receptor agonist has been initially adopted as a treatment and regulator for the Type 2 Diabetes disease. In this essay, we will be focusing on the three primary roles that the semaglutide fulfills throughout day to day life or in potential real world applications. We examined different hormones related to the endocrine system, and identified differences in weaknesses and strengths between GLP-1 and semaglutide. We also assessed the different roles that semaglutide may be used for. The original intended use being Type 2 Diabetes regulation, where we established the utilization of the potent insulin releasing trait of semaglutide being the key factor for Type 2 Diabetes regulation. A repurposed use for weight reduction, where we identified the secondary symptoms of insulin release such as lower appetite. Finally, a speculative application where the diabetes regulation capabilities may have a positive correlation in affecting neurological diseases such as dementia. Through the compilation and review of historic and recent sources, this paper highlights the broader usage of the semaglutide compound. The findings suggest that semaglutide’s mechanisms and variety makes it a promising candidate for future metabolic and potentially groundbreaking neurological medicine.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
[1] Aim for a Healthy Weight. (n.d.). Losing weight, body mass index. National Heart Lung and Blood Institute. https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmi_dis.htm
[2] Atherosclerosis. (n.d.). Causes and risk factors. National Heart Lung and Blood Institute. https://www.nhlbi.nih.gov/health/atherosclerosis/causes
[3] American Diabetes Association. (2024). Understanding Type 2 Diabetes. Diabetes.org; American Diabetes Association. https://diabetes.org/about-diabetes/type-2
[4] Cabou, C., & Burcelin, R. (2011). GLP-1, the Gut-Brain, and Brain-Periphery Axes. The Review of Diabetic Studies, 8(3), 418–431. https://doi.org/10.1900/rds.2011.8.418
[5] Cao, B., Rosenblat, J. D., Brietzke, E., & McIntyre, R. S. (2022). Glucagon-like peptide-1 receptor agonists in Alzheimer’s disease: Mechanisms and clinical implications. Frontiers in Neuroscience, 16, 971467. https://doi.org/10.3389/fnins.2022.971467
[6] Cleveland Clinic. (2023, March 2). Hyperglycemia (High Blood Sugar). Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/9815-hyperglycemia-high-blood-sugar
[7] Dix, M. (2021). Protein Digestion: Enzymes, Absorption, and Ways to Improve Digestion. Healthline. https://www.healthline.com/health/protein-digestion
[8] Drucker, D. J. (2006). The biology of incretin hormones. Cell Metabolism, 3(3), 153–165. https://doi.org/10.1016/j.cmet.2006.01.004
[9] Drucker, D. J. (2018). Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism, 27(4), 740–756. https://doi.org/10.1016/j.cmet.2018.03.001
[10] FDA. (2017). OZEMPIC LABEL [Review of OZEMPIC LABEL]. Access Data FDA; U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf
[11] Friedman, J. M. (2024). The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity. Proceedings of the National Academy of Sciences, 121(39). https://doi.org/10.1073/pnas.2415550121
[12] Furness, J. B. (2012). The enteric nervous system and neurogastroenterology. Nature Reviews Gastroenterology & Hepatology, 9(5), 286–294. https://doi.org/10.1038/nrgastro.2012.32
[13] Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
[14] Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., ... & Brock, B. (2016). In Alzheimer’s disease, six-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: Randomized, placebo-controlled, double-blind clinical trial. Frontiers in Aging Neuroscience, 8, 108. https://doi.org/10.3389/fnagi.2016.00108
[15] Habtemichael, E. N., Qu, L., Verma, S., Soleimani, M., Chiang, S. H., & Saltiel, A. R. (2024). A neuronal circuit that inhibits the brain’s control of insulin secretion and glucose metabolism. Proceedings of the National Academy of Sciences, 121(30), e2415550121. https://doi.org/10.1073/pnas.2415550121
[16] Holst, J. J., Burcelin, R., & Nathanson, E. (2021). GLP-1 and the brain: From appetite regulation to neuroprotection. Nature Reviews Endocrinology, 17(7), 403–415. https://doi.org/10.1038/s41574-021-00511-5
[17] Houston Weight Loss Center. (n.d.). Body mass index. https://www.houstonweightloss.com/weight-loss/body-mass-index/
[18] Knudsen, L. B., & Lau, J. (2019). The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology, 10(155). https://doi.org/10.3389/fendo.2019.00155
[19] Landgraf, D., Neumann, A.-M., & Oster, H. (2017). Circadian clock-gastrointestinal peptide interaction in peripheral tissues and the brain. Best Practice & Research Clinical Endocrinology & Metabolism, 31(6), 561–571. https://doi.org/10.1016/j.beem.2017.10.007
[20] Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., Strauss, H. M., Gram, D. X., Knudsen, S. M., Nielsen, F. S., Thygesen, P., Reedtz-Runge, S., & Kruse, T. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry, 58(18), 7370–7380. https://doi.org/10.1021/acs.jmedchem.5b00726
[21] Li, Y., Zhang, Y., Zhang, X., & Zhang, Y. (2024). Semaglutide ameliorates Alzheimer’s disease pathology and cognitive impairment in APP/PS1 mice and human brain organoids. Biomedicine & Pharmacotherapy, 180, 116564. https://doi.org/10.1016/j.biopha.2024.116564
[22] Manning, B. D., & Toker, A. (2017). AKT/PKB Signaling: Navigating the Network. Cell, 169(3), 381–405. https://doi.org/10.1016/j.cell.2017.04.001
[23] Marucci, G., Buccioni, M., Dal Ben, D., Lambertucci, C., Volpini, R., & Vita, A. (2023). GLP-1 receptor agonists in neurodegenerative diseases: Current status and future perspectives. Frontiers in Neuroscience, 17, 1181190. https://doi.org/10.3389/fnins.2023.1181190
[24] Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022). Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Reviews in Endocrine and Metabolic Disorders, 23(3), 521–539. https://doi.org/10.1007/s11154-021-09699-1
[25] Media Centre | EASD. (n.d.). Www.easd.org. https://www.easd.org/media-centre/home.html#
[26] National Center for Biotechnology Information. (n.d.). Glucagon. PubChem Compound Summary for CID 16132387. Retrieved July 18, 2025, from https://pubchem.ncbi.nlm.nih.gov/compound/Glucagon
[27] National Center for Biotechnology Information. (n.d.). Glucagon-like peptide-1(7-36) amide. PubChem Compound Summary for CID 16133797. Retrieved July 18, 2025, from https://pubchem.ncbi.nlm.nih.gov/compound/Glucagon-like-peptide-1_7-36_-amide
[28] National Institute on Aging. (2023). What happens to the brain in Alzheimer’s disease? Retrieved from https://www.nia.nih.gov/health/what-happens-brain-alzheimers-disease
[29] Novo Nordisk. (2023). Ozempic® (semaglutide) injection [Prescribing information]. https://www.novo-pi.com/ozempic.pdf
[30] Reynolds, M. (2023, June 12). What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know. Wired. https://www.wired.com/story/obesity-drugs-researcher-interview-ozempic-wegovy/
[31] Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine, 8(6), 595–608. https://doi.org/10.15252/emmm.201606210
[32] Semaglutide Injection. (n.d.). SEMAGLUTIDE injection: Medlineplus Drug Information. MedlinePlus. https://medlineplus.gov/druginfo/meds/a618008.html#:~:text=IMPORTANT%20WARNING:%20has%20been%20expanded,risk%20of%20tumors%20in%20humans.
[33] Substantia nigra - an overview | ScienceDirect Topics. (2011). Sciencedirect.com. https://www.sciencedirect.com/topics/neuroscience/substantia-nigra
[34] Temple University Health System. (2023, August 16). Gene that triggers insulin production in gut cells found: Study sheds light on gut’s role in diabetes, and GLP-1. Medical Xpress. https://medicalxpress.com/news/2023-08-gene-triggers-insulin-cells-playing.html
[35] University of Oxford. (2023). Investigating Semaglutide in Amyloid Positivity (ISAP). Oxford Centre for Diabetes, Endocrinology and Metabolism. Retrieved from https://www.rdm.ox.ac.uk/about/our-facilities-and-units/DTU/current-trials/isap
[36] U.S. National Library of Medicine. (2023). Semaglutide in early Alzheimer's disease (NCT04777396). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04777396
[37] Wang, Y., and Mandelkow, E. “Tau in Physiology and Pathology.” Nature Reviews Neuroscience, vol. 17, 2016, pp. 5–21. https://doi.org/10.1038/nrn.2015.1
[38] Wang, Z., Chen, Y., Sun, L., & Liu, J. (2023). Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer’s disease via the GLP‑1R/SIRT1/GLUT4 pathway. Neuropharmacology, 230, 109502. https://doi.org/10.1016/j.neuropharm.2023.109502
[39] Weir, C. B., & Jan, A. (2023). BMI classification percentile and cut off points. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK541070/
[40] Whalley, N., Pritchard, L., & et al. (2011, October). Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells? [Review of Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells?]. Journal of Endocrinology; Journal of Endocrinology. https://joe.bioscientifica.com/view/journals/joe/211/1/99.xml?
[41] Wilding, J. P. H. (2021, February 10). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[42] Woods, S. C., Lutz, T. A., Geary, N., & Langhans, W. (2006). Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philosophical Transactions of the Royal Society B: Biological Sciences, 361(1471), 1219–1235. https://doi.org/10.1098/rstb.2006.1858
[43] Wu, H., Yang, W., Guo, T. et al. Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications. BMC Med 23, 398 (2025). https://doi.org/10.1186/s12916-025-04200-0
[44] Ozempic. (2024, February). Ozempic® Once Weekly Non-Insulin | Ozempic® (semaglutide) injection 0.5 mg or 1 mg. Www.ozempic.com. https://www.ozempic.com/
[45] Zierle-Ghosh, A., & Jan, A. (2023). Physiology, body mass index (BMI). National Library of Medicine; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK535456/